NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: NanoViricides $6 Million Registered Direct Offering and Corporate Overview
TL;DR
NanoViricides secured $6 million in funding, providing capital advantage to advance its broad-spectrum antiviral drug pipeline ahead of competitors.
NanoViricides raised approximately $6 million through a registered direct offering of 3.57 million shares at $1.68 each with attached warrants exercisable at higher prices.
This funding supports NanoViricides' development of antiviral treatments that could improve global health by combating respiratory viruses and other infectious diseases.
NanoViricides is developing nanomedicine treatments for multiple viruses including RSV, COVID, influenza, and shingles using innovative nanotechnology platforms.
Found this article helpful?
Share it with your network and spread the knowledge!
NanoViricides announced a $6 million registered direct offering with concurrent private placement of warrants to a single healthcare institutional investor, involving the purchase of 3,571,429 shares at $1.68 per share.
The company expects gross proceeds of approximately $6 million before expenses through a registered direct offering of common stock at $1.68 per share, along with concurrent private placement of Series A and Series B warrants.
The company will issue Series A warrants exercisable at $1.75 per share (expiring in 2 years) and Series B warrants exercisable at $2.00 per share (expiring in 5.5 years), with both becoming exercisable six months after issuance.
The closing of the offering is expected on or about November 12, 2025, subject to customary closing conditions.
Proceeds will be used for working capital and general corporate purposes to support the company's operations and development programs.
A.G.P./Alliance Global Partners is acting as the sole placement agent for the transaction, and the securities are being purchased by a single healthcare institutional investor.
NanoViricides is a clinical-stage company developing broad-spectrum antiviral nanomedicines using proprietary nanoviricide technology licensed from TheraCour Pharma, Inc.
The lead drug candidate is NV-387 for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, while NV-HHV-1 is being developed for Shingles treatment.
The company is currently focused on advancing NV-387 into Phase II human clinical trials for various viral infections.
The full press release is available at https://ibn.fm/neQCh, and additional company information can be found on their website at www.nanoviricides.com.
Curated from InvestorBrandNetwork (IBN)
